<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00859872</url>
  </required_header>
  <id_info>
    <org_study_id>IIS-0801</org_study_id>
    <nct_id>NCT00859872</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia</brief_title>
  <official_title>Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol IM Injection for Treatment of Acute Psychotic Agitation in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wuhan Mental Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou Mental Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chongqing Mental Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre, open, randomized, haloperidol-referenced, 47 days two treatment
      sessions, parallel-group study.

      After screening period, eligible subjects will be entered 5 days treatment session I to
      compare the efficacy between risperidone oral solution combination clonazepam oral and
      haloperidol IM injection on controlling psychotic agitation, then will be followed by 6
      additional weeks treatment session II for exploring the effect of medicine switching from IM
      injection to oral.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute psychotic agitation is a common problem in many patients with schizophrenia that
      includes agitation, aggression, excitement and violence. An investigation showed that about
      26% psychotic patients were brought to the psychiatric emergency room because of the
      psychotic agitation symptoms. The primary objective is to compare the efficacy between
      risperidone oral solution combination clonazepam oral and haloperidol IM injection on
      controlling psychotic agitation in patients of acute schizophrenia and
      schizophrenic-affective disorder.

      The secondary objectives are: (1) to explore the possibility of decreasing efficacy of acute
      6 weeks treatment from IM injection to oral; (2) to compare the safety between risperidone
      oral solution combination clonazepam oral and haloperidol IM injection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the change of PANSS-EC scores</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate based on the PANSS</measure>
    <time_frame>47 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">198</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>oral group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>risperidone oral solution combination clonazepam oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IM group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>haloperidol IM injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risperidone oral solution</intervention_name>
    <description>risperidone oral solution (2-6mg/d) combination clonazepam (4-8mg/d) oral</description>
    <arm_group_label>oral group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>haloperidol</intervention_name>
    <description>haloperidol IM injection (5-20mg/d)</description>
    <arm_group_label>IM group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women aged 18 to 45 years

          -  DSM-IV diagnosis of acute exacerbation of schizophrenia or schizoaffective disorders

          -  A score of ≥ 14 on a 5-item acute-agitation cluster (including excitement, hostility,
             uncooperativeness and poor impulse control) derived from the PNASS

          -  The total scores ≥60 on the PANSS

        Exclusion Criteria:

          -  Women who are pregnant or breast feeding, or who plan to become pregnant during the
             study

          -  The psychotic agitation is caused by delirium, epilepsy, mental retardation and
             affective disorder; intoxication or symptoms of withdrawal from alcohol or other
             psychoactive substances

          -  Clinical laboratory values indicating serious medical illness

          -  Known hypersensitivity to any of the study medications

          -  Treatment with a depot antipsychotic with 1 cycle of screening

          -  Using of disallowed medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MentalHealth Institute of the 2nd Xiangya Hospital, Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2009</study_first_submitted>
  <study_first_submitted_qc>March 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2009</study_first_posted>
  <last_update_submitted>July 31, 2009</last_update_submitted>
  <last_update_submitted_qc>July 31, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>MentalHealth Institute of the 2nd Xiangya Hospital, Central South University</name_title>
    <organization>the 2nd Xiangya Hospital, Central South University</organization>
  </responsible_party>
  <keyword>acute psychotic agitation</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>risperidone oral solution</keyword>
  <keyword>clonazepam</keyword>
  <keyword>haloperidol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
    <mesh_term>Clonazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

